-
Mashup Score: 0A large-scale proteomics resource of circulating extracellular vesicles for biomarker discovery in pancreatic cancer - PubMed - 8 hour(s) ago
Pancreatic cancer has the worst prognosis of all common tumors. Earlier cancer diagnosis could increase survival rates and better assessment of metastatic disease could improve patient care. As such, there is an urgent need to develop biomarkers to diagnose this deadly malignancy. Analyzing circulat …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 22Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial - 6 month(s) ago
Nature Medicine – In an ongoing phase 1 trial, the combination of two new immunotherapies targeting CTLA-4 and PD-1 was overall well tolerated and elicited encouraging clinical responses in…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
🔥🔥Hot of the press. #Botensilimab, a next-generation CTLA4 inhibitor, plus Balstilimab eliciting responses in cold MSS #ColonCancer. @OncoAlert https://t.co/UT0Fol0VK1
-
-
Mashup Score: 22Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial - 6 month(s) ago
Nature Medicine – In an ongoing phase 1 trial, the combination of two new immunotherapies targeting CTLA-4 and PD-1 was overall well tolerated and elicited encouraging clinical responses in…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
🔥🔥Hot of the press. #Botensilimab, a next-generation CTLA4 inhibitor, plus Balstilimab eliciting responses in cold MSS #ColonCancer. @OncoAlert https://t.co/UT0Fol0VK1
-
-
Mashup Score: 22Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial - 6 month(s) ago
Nature Medicine – In an ongoing phase 1 trial, the combination of two new immunotherapies targeting CTLA-4 and PD-1 was overall well tolerated and elicited encouraging clinical responses in…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
🔥🔥Hot of the press. #Botensilimab, a next-generation CTLA4 inhibitor, plus Balstilimab eliciting responses in cold MSS #ColonCancer. @OncoAlert https://t.co/UT0Fol0VK1
-
-
Mashup Score: 22Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial - 6 month(s) ago
Nature Medicine – In an ongoing phase 1 trial, the combination of two new immunotherapies targeting CTLA-4 and PD-1 was overall well tolerated and elicited encouraging clinical responses in…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
🔥🔥Hot of the press. #Botensilimab, a next-generation CTLA4 inhibitor, plus Balstilimab eliciting responses in cold MSS #ColonCancer. @OncoAlert https://t.co/UT0Fol0VK1
-
-
Mashup Score: 22Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial - 6 month(s) ago
Nature Medicine – In an ongoing phase 1 trial, the combination of two new immunotherapies targeting CTLA-4 and PD-1 was overall well tolerated and elicited encouraging clinical responses in…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
🔥🔥Hot of the press. #Botensilimab, a next-generation CTLA4 inhibitor, plus Balstilimab eliciting responses in cold MSS #ColonCancer. @OncoAlert https://t.co/UT0Fol0VK1
-
-
Mashup Score: 22Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial - 6 month(s) ago
Nature Medicine – In an ongoing phase 1 trial, the combination of two new immunotherapies targeting CTLA-4 and PD-1 was overall well tolerated and elicited encouraging clinical responses in…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
🔥🔥Hot of the press. #Botensilimab, a next-generation CTLA4 inhibitor, plus Balstilimab eliciting responses in cold MSS #ColonCancer. @OncoAlert https://t.co/UT0Fol0VK1
-
-
Mashup Score: 22Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial - 6 month(s) ago
Nature Medicine – In an ongoing phase 1 trial, the combination of two new immunotherapies targeting CTLA-4 and PD-1 was overall well tolerated and elicited encouraging clinical responses in…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
🔥🔥Hot of the press. #Botensilimab, a next-generation CTLA4 inhibitor, plus Balstilimab eliciting responses in cold MSS #ColonCancer. @OncoAlert https://t.co/UT0Fol0VK1
-
-
Mashup Score: 2Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer - 3 year(s) ago
Purpose: Pancreatic ductal adenocarcinoma (PDAC) remains a significant health issue. For most patients, there are no options for targeted therapy, and existing treatments are limited by toxicity. The HOPE trial (Harnessing Organoids for PErsonalized Therapy) was a pilot feasibility trial aiming to prospectively generate patient-derived organoids (PDO) from patients with PDAC and test their drug…
Source: Clinical Cancer ResearchCategories: Hem/Oncs, Latest HeadlinesTweet-
Correlating Organoid sensitivity to clinical responses in Pancreatic cancer. Great work from @DrMhidalgo @3dorganoid and Joe Grossman that I had the privilege to collaborate with https://t.co/hIpQA9X69s
-
-
Mashup Score: 1Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer - 3 year(s) ago
Purpose: Pancreatic ductal adenocarcinoma (PDAC) remains a significant health issue. For most patients, there are no options for targeted therapy, and existing treatments are limited by toxicity. The HOPE trial (Harnessing Organoids for PErsonalized Therapy) was a pilot feasibility trial aiming to prospectively generate patient-derived organoids (PDO) from patients with PDAC and test their drug…
Source: Clinical Cancer ResearchCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @JoeGrossman7: https://t.co/zN8IQjSO52 Thank you to #pancreaticcancer patients, mentors, collaborators, and everyone who made this possi…
-
A large-scale proteomics resource of circulating extracellular vesicles for biomarker discovery in pancreatic cancer https://t.co/2aQuZh8Zrd